Author Archives: Denise Bell
Senator Mike Lee Urges Action for Transitional Coverage of Innovative Med Tech
Senator Mike Lee (R-UT) and a group of like-minded colleagues are preparing to send a letter to CMS Administration Chiquita Brooks-LaSure urging the agency to issue a proposed rule by year’s end to provide accelerated Medicare coverage for emerging medical technologies. Medicare patients should have timely access to innovative and beneficial care, which can change […]
BIOHIVE STEM SEPTEMBER KICK-0FF
Last week, BioHive kicked off its celebration of “STEM September” with an evening of networking in downtown Salt Lake City. Life sciences professionals joined from all over the Salt Lake Valley to connect with the industry and support the efforts of BioHive. “I was so inspired hearing stories from the people that make Utah’s life […]
Rep. Burgess Owens Spends a Day in the BioHive
Utah life sciences companies took center stage September 2, as U.S. Representative Burgess Owens (R-UT) toured Canyon Labs, Ultradent (Canyon Labs’ parent company), Ortho Development and Xenter – all innovative leaders in advancing medical technologies that improve patient care and provide jobs for hundreds of Utahns. BioUtah helped to facilitate the BioHive day. “Utah is […]
Senator Mike Lee Spends a Day in the BioHive
U.S. Senator Mike Lee (R-UT) on August 15 spent the day connecting with Utah’s life sciences community, known as the BioHive, touring facilities at BD, IONIQ Sciences, SEEK Labs and Carterra. His schedule also included a tour of Altitude Lab in the University of Utah’s Research Park where he led a roundtable discussion with nearly […]
Sumitomo Pharma Oncology Receives Orphan Drug Designation for DSP-5336, an Investigational Menin and Mixed-Lineage Leukemia Binding Protein for Treatment of Acute Myeloid Leukemia
Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for DSP-5336, an investigational small molecule inhibitor against the binding of menin and mixed-lineage leukemia (MLL) protein, for the treatment of acute myeloid leukemia (AML). “We are pleased to have […]
Senate Democrats Push Drug Pricing, Tax, Climate Package
Sen. Joe Manchin (D-W. Va.) on Wednesday said he had signed off on a revised “Build Back Better” plan, renamed the “Inflation Reduction Act of 2022,” which includes sweeping drug price controls along with tax increases and billions for climate and energy spending. The bill’s drug pricing provisions would allow Medicare to negotiate drug prices […]
BioUtah Joins State BIOs in Opposing Drug Price Controls
Senate Democrats are inching closer to a vote on a revived “Build Back Better” package, largely focused on drug pricing. The package would give Medicare the authority to negotiate drug prices and impose inflation rebates. The negotiation process, in practice, would function more like government price controls since drug manufacturers deemed non-compliant with the requirements […]
Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of Myelofibrosis
Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, recently announced that the FDA granted Orphan Drug Designation for TP-3654, the company’s proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis. “This designation is an important milestone in the development of TP-3654 and highlights the need for potential new treatment […]
Sumitomo Pharma Oncology, Inc. Pursues Research and Discovery with Persistence – Featured in Pharma Tech Outlook
Sumitomo Pharma Oncology, Inc. (SMP Oncology) and Steve Warner, Ph.D., Senior Vice President and Head of US Research at SMP Oncology, were recently featured in a Pharma Tech Outlook. In “Sumitomo Pharma Oncology: Discovering Immunotherapy Agents with Persistence,” Dr. Warner discusses SMP Oncology’s ongoing work in immunotherapy drug discovery, highlighting the progress with the Company’s […]
Invest Lithuania
BioUtah has established a partnership with Invest Lithuania, an arm of the Lithuanian government focused on developing life sciences in their country. The life sciences sector in Lithuania is regarded as one of the most highly developed in Central and Eastern Europe (CEE). The sector is driven by innovation and aims to become Europe’s next […]
BioHive Takes the Stage at One Utah Summit
The BioHive community was featured prominently at the One Utah Summit held on May 10 at the Grand America Hotel in Salt Lake City. Speakers from the life sciences industry addressed the crowd on topics ranging from job creation and talent development to life-saving innovation and drug discovery. Tom Polen, CEO of BD, and Rob […]
Recursion Co-Founder and CEO, Chris Gibson, Awarded Governor’s Medal for Science and Technology
Recursion Co-founder and CEO, Chris Gibson, Ph.D., was honored at the One Utah Summit on May 10, receiving the Governor’s Medal for Science and Technology. Gov. Spencer Cox presented the award during the summit’s special recognition ceremony. The prestigious award commends the distinguished service, significant achievement, and positive economic impact of individuals to the state […]
